MAM
Hinduja Group appoints Anand Agarwal as group president – finance
MUMBAI: Money talks and so does experience. In a move that signals serious intent for its next phase of growth, the Hinduja Group has roped in financial veteran Anand Agarwal as group president of Finance. With a career spanning nearly three decades and multiple sectors, Agarwal is expected to steer the conglomerate’s financial strategy with a steady, seasoned hand.
Agarwal brings to the table heavyweight credentials, he’s a chartered accountant, company Secretary, ICWA, CFA, and an executive MBA from IIM Ahmedabad. His résumé reads like a who’s who of Indian industry: Chambal Fertilisers (as CFO), Tata Power, Peepul Capital PE, AGS Transact Technologies, Aditya Birla Group, Reliance Industries, and ITC Limited.
He has successfully raised capital from global private equity giants, pension funds, and sovereign wealth funds, and helmed several high-stakes M&A deals across the Agri Inputs, Infrastructure (Power), FMCG, Cement, Metals, and Financial Services sectors.
As group pof Hinduja Group HR Amit Chincholikar put it, “With the Group’s businesses entering a phase of strategic expansion, strong financial leadership is crucial. Anand’s vast experience in corporate finance and M&A, along with his proven ability to manage large-scale financial strategies, will be key in driving the Group’s growth.”
Agarwal, too, sounds ready to get down to business: “My focus will be on enhancing financial efficiency, optimising capital deployment, and supporting the Group’s expansion plans.”
With Agarwal’s appointment, the Hinduja Group appears poised to fine-tune its financial engine accelerating towards a future built on bold strategy, smart capital, and sharper execution.
MAM
Beacon Group appoints Dr Rajesh Patel as Group CEO
36-year healthcare veteran to lead Beacon Diagnostics, Vector Biotek, Biogeny.
MUMBAI: A new chief, a fresh diagnosis and a sharper prescription for growth. Beacon Group has appointed Dr Rajesh Patel as its Group Chief Executive Officer, effective April 1, 2026, signalling a decisive push to scale its presence in the diagnostics and IVD space. Patel steps into the role with 36 years of experience across the healthcare and diagnostics industry, bringing a career shaped by leadership roles spanning sales, marketing, business development and operational strategy. His mandate is both expansive and precise: to steer the group’s overall strategic direction while tightening coordination across its three core entities Beacon Diagnostics, Vector Biotek and Biogeny Diagnostics.
In practical terms, that means driving cross-company synergies, accelerating market expansion and strengthening organisational capability areas increasingly critical as diagnostic players compete for scale in a fragmented yet rapidly evolving healthcare ecosystem. The group is positioning itself to capture unmet demand across chain laboratories, key accounts and standalone labs, segments that remain underserved despite growing diagnostic needs.
The appointment comes at a time when the In Vitro Diagnostics (IVD) sector in India is entering a more competitive and innovation-led phase, with companies focusing not just on product pipelines but also on service delivery, integration and customer-centric models. Beacon’s leadership appears to be betting that Patel’s execution-focused approach can help translate ambition into operational momentum.
Welcoming the appointment, Chairman Dr D K Joshi described Patel’s induction as a strategic move aligned with the group’s long-term vision, emphasising the role of leadership depth in navigating the next phase of growth.
For Beacon Group, the message is clear, in a sector where precision matters, leadership is the new differentiator—and this appointment is intended to set the tone for what comes next.
